Inside India’s qPCR Transformation: Scale, Shift, and Structural Change

Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine

Over the past 15–20 years, I have seen real-time PCR (qPCR) in India evolve from a niche research capability into a frontline diagnostic necessity. What used to sit inside elite research institutes is now embedded across hospital labs, diagnostic chains, and increasingly, near-patient settings.

This transition hasn’t been linear—it has been shaped by infrastructure gaps, pricing pressures, regulatory shifts, and one major inflection point: the COVID-19 pandemic.

Market Reality: Not Just Growth, but Structural Expansion

On paper, India’s PCR market is growing at around 6–8% CAGR, but that headline figure doesn’t fully reflect what’s happening on the ground. In practice, instrument placement is no longer the primary bottleneck—utilization is. The market has clearly shifted from capex-driven sales to a reagent-led, recurring revenue model, where ongoing assay consumption matters more than one-time instrument sales. At the same time, buying decisions have evolved from being research-led to becoming strongly driven by ROI and throughput considerations.

In large diagnostic chains, a qPCR system is now expected to run multiple assays daily while delivering fast turnaround times (TAT). As a result, real growth in this market is not just about placing more machines, but about maximizing assay volumes and continuously expanding the test menu.

Instrument and Service Providers

The Indian research and molecular diagnostics market is highly competitive, characterized by a mix of global multinational leaders, strong domestic diagnostic networks, and emerging local biotech players. Global companies such as Thermo Fisher Scientific, Roche, Abbott Laboratories, QIAGEN, Bio-Rad Laboratories, and Agilent Technologies dominate the high-end research and clinical diagnostics segments, competing through advanced platforms, broad assay menus, and strong regulatory credibility. Danaher Corporation (via Cepheid) and bioMérieux are also key players, particularly in cartridge-based and syndromic testing solutions.

At the same time, India’s ecosystem includes rapidly growing domestic players such as Molbio Diagnostics, Mylab Discovery Solutions, and 3B BlackBio Dx, which are gaining traction through cost-effective, portable, and locally manufactured PCR solutions aligned with government initiatives like “Make in India.” Additionally, large diagnostic service providers such as Dr. Lal PathLabs, Metropolis Healthcare, and Thyrocare play a crucial role in driving demand and adoption by expanding molecular testing across urban and semi-urban markets.

Overall, competition in India is shaped by a clear divide: multinational companies dominate premium, high-throughput and hospital segments, while Indian and emerging players compete on affordability, decentralization, and accessibility—making the market both highly competitive and structurally dynamic.

Evolution: From Research Tool to Clinical Engine

Early in my experience, Real Time PCR systems were primarily installed in academic labs, used for gene expression and validation work, and operated by highly trained scientists. Today, the same technology is widely used by technicians in routine diagnostics, standardized through ready-to-use kits and protocols, and seamlessly integrated into clinical workflows. The biggest shift has been from an open, expertise-dependent system to a closed, workflow-driven model. This transition has significantly improved scalability, but it has also led to a degree of commoditization in certain segments of the market. 

 Hospital & Diagnostic Lab Adoption: What’s Actually Driving It

In real-world sales and deployment, three key triggers consistently drive adoption. First is test menu expansion, as hospitals increasingly look to move beyond traditional biochemistry and immunoassays into molecular testing. Second is clinical demand pull, with doctors now expecting PCR-based confirmation for infectious diseases, oncology markers, and other high-value specialty tests. Third is competitive pressure—once one hospital or diagnostic lab offers PCR capabilities, others tend to follow to avoid losing patients. However, an important nuance is that adoption differs by segment: Tier-1 labs typically prioritize high-throughput automated systems, while Tier-2 and Tier-3 labs lean toward compact, cost-optimized solutions

 COVID-19: The Single Biggest Market Accelerator

Before the COVID-19 pandemic, PCR/ Real Time PCR adoption in India was steady but relatively limited, largely confined to specialized labs and select diagnostic centres. During the pandemic, however, there was an unprecedented transformation—labs scaled from running tens of tests per day to thousands, government approvals accelerated at a pace never seen before, and even labs with no prior molecular experience rapidly entered the Molecular diagnostics space. From an industry standpoint, COVID fundamentally reshaped the landscape by creating infrastructure at scale, training an entirely new workforce, and normalizing Real Time PCR in public awareness. Post-COVID, the challenge I now observe is different: it’s no longer about building capacity, but about effectively repurposing that expanded infrastructure for non-COVID testing and ensuring sustained utilization.

Rise of Point-of-Care PCR: Reality vs Hype

 There’s strong buzz around portable and cartridge-based PCR systems, but in practice, adoption is nuanced. From what I’ve seen, real traction is emerging in emergency settings such as ICUs and ERs, in smaller hospitals that lack full-fledged molecular labs, and in infectious disease testing where turnaround fast time is critical. On the other hand, adoption is slower in price-sensitive labs and in high-volume central laboratories, where conventional qPCR remains more economical. The fundamental trade-off is clear: point-of-care PCR offers speed and simplicity, while traditional qPCR delivers cost efficiency and scalability. Ultimately, the players who succeed will be those who can effectively balance both models.

Point-of-care (POC) PCR is gaining traction in settings where speed and immediate clinical decision-making matter more than cost. It’s most impactful applications include acute infectious diseases such as COVID-19, influenza, and respiratory panels, particularly in ER and ICU settings where results are needed in under an hour. It has also seen large-scale deployment in tuberculosis programs across India, enabling rapid detection of both infection and drug resistance in decentralized environments. In critical care, POC PCR supports faster diagnosis of conditions like sepsis, meningitis, and bloodstream infections, allowing timely and targeted therapy. It is also valuable in managing hospital-acquired infections, including MRSA and antimicrobial resistance markers, aiding infection control efforts. Emerging use cases in oncology, such as rapid mutation testing (EGFR, KRAS), are helping accelerate treatment decisions, while applications in neonatal and maternal care improve outcomes by enabling early detection of infections and reducing empirical antibiotic use. Additionally, POC PCR plays a crucial role in expanding access to diagnostics in Tier-2, Tier-3, and rural areas by extending testing beyond centralized labs.

From a ground reality perspective, POC QPCR works best in ICUs, TB programs, and emergency diagnostics, but its adoption remains limited in high-volume routine testing due to cost constraints. Ultimately, it complements rather than replaces central lab —offering speed and immediacy, while conventional PCR provides scale and cost efficiency. Going forward, growth in India will depend on achieving the right balance through cost reduction, simplified workflows, and broader decentralization.

Ground-Level Challenges No One Talks About Enough

From practical experience, several real friction points consistently impact adoption and long-term success. Cost sensitivity remains the biggest barrier, with tight capital budgets and reagent pricing directly influencing purchasing decisions and ongoing usage. Underutilization is another major issue, as many installed systems operate below capacity, often due to a limited or poorly planned test menu, resulting in low return on investment. Training gaps further complicate matters, with significant variability in skill levels outside metro cities and a high dependence on application support. In addition, regulatory ambiguity—driven by evolving compliance requirements and inconsistent validation expectations—adds another layer of complexity. In short, selling a system is relatively easy; sustaining its utilization is the real challenge.

India’s Biggest Opportunity: Decentralization + Localization

This is where I see the strongest future potential. India does not have the luxury of relying solely on centralized testing, and there is clear demand across Tier-2, Tier-3, and rural markets. Decentralized diagnostics, particularly point-of-care and near-patient PCR, can significantly expand access and bridge existing gaps in healthcare delivery. At the same time, local manufacturing presents a major opportunity, given the current dependence on imported reagents and instruments and the growing push toward domestic production. This creates a favourable environment for Indian players to compete effectively on cost. Ultimately, success in this market will be defined by affordable pricing models, robust after-sales support, simplified workflows, and reliable supply chains.

Final Perspective

If I had to summarize the journey, real-time PCR has evolved from a research-driven tool with niche adoption, to a diagnostic backbone scaled massively in the post-COVID-19 pandemic era, and is now heading toward a future that is decentralized, cost-optimized, and increasingly locally driven. It is no longer just a technology—it is becoming a foundational layer of healthcare infrastructure in India. Importantly, the next phase of growth will not be defined by innovation alone, but by the ability to execute at scale in a highly price-sensitive and operationally complex market.

 About Author: Jai R Nair is a Business Leader with 21 years of experience in sales, marketing and operations for companies including fortune 500 companies in the biotechnology and life sciences sector.